Podcasts about Azim

Join Corey Quinn and Azim Nagree—Head of M&A at Herringbone Digital—as they unpack the M&A process for digital agencies looking to scale, exit, or acquire. Azim shares what acquirers really look for, why specialization boosts valuation, and how to prepare your agency for a successful acquisition or exit. With deep expertise in scaling revenue engines and improving retention, Azim offers actionable insights on due diligence, financing options, and communicating with clients and employees during transitions. Whether you're looking to buy, sell, or simply grow smarter, this conversation is packed with practical advice for agency leaders. Tune in! Episode Highlights: - The Exit Strategy Few Agencies Plan For — And why waiting too long could cost you millions. - The Real Value of Specialization — How niching down boosts agency valuation in M&A. - Seller Financing Decoded — When it works, when it doesn't, and how to use it to your advantage. - What Buyers Are Really Looking For — Hint: it's not just your client roster. - Due Diligence Dealbreakers — The hidden issues that kill agency acquisitions before they close. - M&A on a Budget — How smaller agencies can still play (and win) in the acquisition game. - The One Metric That Makes or Breaks a Sale — And why most agencies overlook it. - AI's Role in Your Next Deal — Why automation and innovation could tip the scales in your favor. - The Communication Mistake That Spooks Clients — How to keep trust intact during a transition. - Buying Without Breaking — How to align culture and systems when acquiring another agency. The resources mentioned in this episode are: - Connect with Azim Nagree on LinkedIn: https://www.linkedin.com/in/azimnagree - Learn more about Herringbone Digital: https://www.herringbonedigital.com - Escape the generalist trap with my best-selling book “Anyone, Not Everyone” and discover how to become the go-to agency in a vertical market https://www.AnyoneNotEveryone.com

Brought to you with the support of Simpson Helmets! Danger Dan is back for his 13th wild takeover of the Mama Tried / Flat Out Friday Podcast! This time, he sits down with the incredible Kiki Azim of Rebels With a Cause — a fearless group leading unforgettable motorcycle tours through Pakistan while also giving back through humanitarian aid and community support. From ripping through the Himalayas to building bridges between cultures, Kiki shares stories of adventure, purpose, and the powerful mission behind Rebels With a Cause. It's an episode full of grit, heart, and high-octane inspiration.  Listen now and get inspired to ride with purpose.  https://www.instagram.com/rebels_withacause/ Learn more: https://www.rebelstour.com/  Don't forget to like, comment, and subscribe!  #MamaTried #FlatOutFriday #DangerDan #MotorcycleTours #PakistanMotorcycleAdventure #RebelsWithACause #MotoCulture #PodcastTakeover #RideWithPurpose

Adam Azim and David Benavidez notched the finest wins of their careers last weekend and, with feet on the ground and context at hand, we examine the performances of each. What's next, ideally, for both fighters? We review the subject of post-fight pandemonium, briefly ponder the likelihood of PEDs being rife among the elite and journey back in time.We land in 1989 when Lloyd Honeyghan and Marlon Starling were the premier welterweights and Mike Tyson grew tired of Harry Carpenter. Get bonus content on Patreon Hosted on Acast. See acast.com/privacy for more information.

iFLTV'S Kugan Cassius sat down for an EXCLUSIVE 40 MINUTE sit down with Matchroom kingpyn EDDIE HEARN, who discussed Joshua next fight, Canelo v Jake Paul / Crawford, Benn v Eubank, Smith v Azim & more! Learn more about your ad choices. Visit megaphone.fm/adchoices

Seconds out, round 233! Join your hosts Kam & Flowz this week for another boxing roundup! Azim vs Lipinets review (1:45) Benavidez vs Morrell Jr review (20:45) Fulton vs Figueroa II review (42:15) Chisora vs Wallin preview (51:00) Get involved with the discussion on Twitter using the hashtag #StrapSZN Instagram: @strapsznpodcast Twitter: @strapsznpod We are available on all good streaming platforms. Hit the url below to get direct links to all our streaming pages. Give us a follow, leave us a review and connect with us! https://allmylinks.com/strapsznpodcast

Join Adam Smith and Spencer Oliver as they look back at the Adam Azim vs Sergey Lipinets weigh-in, ahead of their fight on Saturday, live on talkSPORT. Martin Bakole also joins the boys to discuss his heavyweight prospects. Hosted on Acast. See acast.com/privacy for more information.

Seconds out, round 232! Boxing aficionados Kam & Flowz take you through this weeks hot boxing topics! Inoue vs Kim review (1:55) Smith vs Ouizza review (6:20) Pacheco vs Nelson review (14:00) Azim vs Lipinets preview (28:20) Benavidez vs Morrell Jr preview (33:50)  Get involved with the discussion on Twitter using the hashtag #StrapSZN Instagram: @strapsznpodcast Twitter: @strapsznpod We are available on all good streaming platforms. Hit the url below to get direct links to all our streaming pages. Give us a follow, leave us a review and connect with us! https://allmylinks.com/strapsznpodcast

Bu bölümde "Azim: Sabır, Tutku ve Kararlılığın Gücü" kitabı üzerine konuşuyoruz.Mücadele'ye hoş geldiniz. Twitter'dan Mücadele'yi takip etmeyi unutmayın: twitter.com/mucadelepodcastBizi dinleyebileceğiniz tüm platformlar:Spotify: https://open.spotify.com/show/3wZOwKwgFBsGmfG4ucjdd1Apple Podcasts: https://podcasts.apple.com/tr/podcast/m%C3%BCcadele/id1360454797?l=tr?l=trSpreaker: https://www.spreaker.com/show/3093942YouTube: / @mucadelepodcastHer türlü geri bildiriminiz için;mucadelepodcast@gmail.com twitter.com/mucadelepodcastadreslerinden bize ulaşabilirsiniz. Keyifli dinlemeler!

iFL TV's Joe Pugh speaks to boxing promoter Ben Shalom at the launch press conference for Azim vs Lipnets. He speaks about the miscommunication between himself and trainer Joe Galagher, rebuilding his fractured relationship with Eddie Hearn & Chris Eubank Jr vs Conor Benn latest.

Kitap Özeti: Azim: Sabır, Tutku ve Kararlılığın Gücü - Angela DuckworthHer türlü geri bildiriminiz için; mucadelepodcast@gmail.com adresinden bize ulaşabilirsiniz. Keyifli dinlemeler!

Now for the conclusion of my two part conversation with Kiki Azim and Kirsten Midura.  In our previous episode #80, you could hear it in their voices.  A passion for empowering our motorcycling community to find peace of mind by demonstrating a love for others.  The poor, the innocent, those who believe that no one cares for them.  So how do you demonstrate a love for others?  Volunteer, donate or both!  You're blessed with the opportunity to find joy riding your motorcycle. Now you can bring that joy to others who really need it.  Click the links in the show notes for details or feel free to email me at ron@peacelovemoto.com for specific information.You can help!  Make your tax-deductible donation TODAY!Engines for Change:  https://www.enginesforchange.org/Rebels with a Cause:  https://www.rebelstour.com/Rebels donations:  https://givebutter.com/E4C-Rebels-With-A-Cause

Today, we hear part 1 of my fascinating conversation with Kiki Azim and Kirsten Midura.  Two friends with a common heart.  A common love for motorcycling and a shared passion for healing a hurting world.  People like them have changed the world!  You can too! You can help!  Make your tax-deductible donation TODAY!Engines for Change:  https://www.enginesforchange.org/Rebels with a Cause:  https://www.rebelstour.com/Rebels donations:  https://givebutter.com/E4C-Rebels-With-A-Cause

iFL TV's Joe Pugh speaks to Ben Shalom as he announces Azim vs Lipinets. He speaks about Buatsi vs Smith, Simpson vs Woodall and an update on Chris Eubank Jr vs Conor Benn.

Hosted on Acast. See acast.com/privacy for more information.

Ade Oladipo and Gareth A Davies reflect on an impressive performance from Adam Azim, who saw off Ohara Davies on Saturday night to further establish himself as one of the best prospects in the countryAnthony Yarde also returned but looked less impressive in his win over Ralf Vilcans, looks like Joshua Buatsi next for himPLUS, we discuss what next for Riyadh Season in the aftermath of October 12th, we look ahead to Catterall vs Prograis and discuss an emotional and devastating return for Francis Ngannou in the PFL Hosted on Acast. See acast.com/privacy for more information.

The Boxing Show returns as Boxing News' Rob Tebbutt is joined by Barry Jones and Andy Clarke as they review the weekend's action, including Adam Azim's stoppage win over Ohara Davies, Lewie Edmondson's narrow win over Dan Azeez and Bakhram Murtazaliev's three round demolition of Tim Tszyu in Orlando.

3 divs break down the full Beterbiev Bivol card and looks at what's next for everyone... Hosted on Acast. See acast.com/privacy for more information.

This week Andy Scott and Gary Logan are joined by WBC featherweight world champion Skye Nicolson to look back at that dramatic night in Riyadh. They discuss all the talking points from the Beterbiev v Bivol bill including Ben Whittaker's injury, Wardley's explosive win and the scoring of the main event.Light heavyweight contender Anthony Yarde also joins the podcast and reveals his opponent for Saturday's Azim v Davis bill at the Copper Box Arena. 

Lets av a chat about Canelo Berlanga and Adam Azim then a fat heated debate on a regular topic Hosted on Acast. See acast.com/privacy for more information.

LVR's 2024 President, Merri Perry sits down with 2024 BORPAC Chair Azim Jessa to talk about some wild stories where RPAC/PSF funds helped protect property owners all over the country, how those donations inspire change in the market, and the truth about rent control! If you're a REALTOR® member and ever wondered exactly what donating to the RPAC Political Survival Fund does, this is your chance to learn exactly how those dollars make huge changes for individuals and the real estate market as a whole. Members can make contributions to BORPAC/RPAC/PSF today here: https://borpaclv.com To learn all about the truth about Rent Control, visit https://truthaboutrentcontrol.com If you have any questions about BORPAC or want to be more involved, contact Azim Jessa directly at azim@jessagroup.com

In this episode of JCO Article Insights, Dr. Giselle de Souza Carvalho interviews Dr. Hatem Azim and Dr. Ann partridge on their JCO article “Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy,” TRANSCRIPT Giselle Carvalho: Welcome to the JCO Article Insights episode for the August issue of the Journal of Clinical Oncology. This is Giselle Carvalho, your host. I'm a Medical Oncologist in Brazil focusing on breast cancer and melanoma skin cancers, and one of the ASCO editorial fellows at JCO this year. Today, I will have the opportunity to interview Dr. Hatem Azim and Dr. Ann Partridge, two of the authors of the POSITIVE trial. We will be discussing their trial on “Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy,” which was published in May this year.  Hello, Dr. Azim and Dr. Partridge. Welcome to our podcast. Dr. Ann Partridge: Hi. Thanks. Dr. Hatem Azim: Hello. Giselle Carvalho: So, beginning with our interview for breast cancer survivors, in addition to the treatment itself, aging is one of the major contributors to infertility. The optimal duration of adjuvant endocrine therapy in patients with hormone positive early breast cancer ranges from five to ten years, depending on patient and tumor characteristics. This time interval can be critical for women who wish to attempt pregnancy. One of the main concerns in daily breast cancer oncology practice is whether breast cancer recurrence rates are increased either by temporary interruption of endocrine therapy for pregnancy or by the use of assisted reproductive technologies. Dr. Azim, what about assisted reproductive technology is worrisome regarding breast cancer outcomes? And how do the POSITIVE study results address the concern about worsening breast cancer outcomes either with assisted reproductive technology or endocrine therapy interruption? Dr. Hatem Azim: So, in the primary analysis of the POSITIVE trial, we tried to address one of these questions, whether temporary interruption with endocrine therapy affects breast cancer outcome. And what we found was that interruption did not appear to have a detrimental impact at the median follow up of 41 months. So in the current manuscript, we addressed the second question, whether assisted production of fertility preservation has an impact as well on breast cancer outcome. And we did not find any worsening of outcomes in patients who underwent these procedures compared to those who had a spontaneous pregnancy. Of course, we have relatively short follow up, but at least the outcomes at the median follow up of around 3 to 4 years appears to be reassuring. Giselle Carvalho: I see. Thank you. These are really important outcomes regarding premenopausal patients. So, moving on, results from your study show that after 24 months, 80% of women under 35 years old had at least one successful pregnancy, while the same was true for 50% of women aged 40 to 42. These results are particularly impressive considering that over 60% of women over 35 had undergone chemotherapy.  Dr. Partridge, other than age, what factors did you find were associated with a successful pregnancy?  Dr. Ann Partridge: Yeah. The biggest factor, other than age, that was associated with successful live birth pregnancy was use of assisted reproductive technologies. So either having gone through IVF prior to diagnosis and banking eggs or embryos prior to diagnosis and then using them during the study, for undergoing stimulation of the ovaries during the study and then using it during the study. And that's what we also looked at in this most recent analysis of the initial POSITIVE data.  Giselle Carvalho: I see. Thank you. The group of patients who underwent embryo oocyte cryopreservation at diagnosis were more likely to be nulliparous and treated with chemotherapy. Presumably these represent the patient group most afraid they will be infertile, as they would be receiving chemotherapy, and most desirous of pregnancy, as they had not yet had any children. Fertility preservation techniques are expensive and not easily available for all patients, particularly in less wealthy countries. Is there any group of your breast cancer patients with a high enough likelihood of pregnancy without assisted reproductive technology that you would not recommend this?  Dr. Ann Partridge: Sure. So we are so glad to have assisted reproductive technologies available in many places, but as you know, they're not available everywhere. And even where they're available for some people, it's either inaccessible for a number of reasons or it doesn't feel right emotionally or ethically. And then finally, sometimes people need fairly quick treatment and they just don't have the time, even though we don't think there are long delays. And so we do and are able to know who can get pregnant after standard chemotherapy. Not perfectly, but we can give estimates. And the gestalt is, the younger a woman is, the less likely she is to become amenorrheic and the associated infertile, although it's not a perfect match in terms of amenorrhea being a surrogate. And then there are particular chemotherapy regimens that are more gonadotoxic than others. The more cyclophosphamide, for example, or alkylating agent, the more anthracycline, the higher the likelihood generally of causing at least amenorrhea and likely infertility. The huge caveat there is that for some of our newer therapies, we have no good information about how they might impact on menstrual status, let alone the actual rates of fertility. So we need to collect those data. But certainly, if someone's very young, they're going to get four cycles of TC or they have inflammatory breast cancer, we often take kind of a let the chips fall where they may approach, because they just aren't able to access it and we'll often do something like ovarian suppression through the chemotherapy to help support them and hope that it improves their menstrual functioning in the long run and/or fertility. Giselle Carvalho: Thank you for your insight. So you found that pregnancy incidence over time differed by age group, although incidence of menstrual recovery over time was similar across all age groups, which I conclude that menstrual recovery does not translate into fertility. The addition of gonadotropin releasing hormone analogs to chemotherapy was not associated with time to pregnancy. However, of course, such use was not randomized.  Dr. Azim, if assisted reproductive technology is not available to patients for reasons such as socioeconomic factors, would you recommend using GnRH analogs with chemotherapy for the purpose of fertility preservation?  Dr. Hatem Azim: Yes. The short answer is yes. Of course, POSITIVE study was not designed to address the question around GnRH analogs, but we do have several randomized studies and meta analyses that have shown clearly that the use of GnRH analogs with chemotherapy reduce the risk of premature ovarian insufficiency. And subgroup analysis of some of these studies have shown a trend towards higher pregnancy rates as well. So, of course, if a patient does not have access to assist reproductive technology, GnRH analogs in combination with chemotherapy represent a very good alternative.  Giselle Carvalho: I see. Thank you. Thank you for your response. At enrollment, 93.2% of women on POSITIVE trial had stage 1 or 2 disease and 66% had no negative disease. Therefore, one possible bias is that investigators might have been more comfortable with temporarily interrupting endocrine therapy if the risk of relapse was low. Dr. Partridge, what recommendations would you have for women with stage three hormone receptor positive breast cancer who desire to attempt pregnancy? Dr. Ann Partridge: Yeah, thank you. That's a really good question. It comes up in our tumor boards and discussions about patient care all the time, and I think, as you know, only a small proportion, about 6%, had stage 3 disease. Those patients are at higher risk of recurrence by nature of their stage. Not that all stage 3 are created equal, because, of course, if someone had a complete pathologic response to preoperative therapy and their stage 3 disease at diagnosis went to a PCR, then that person may have even better outcomes in the long run than someone who had postoperative treatment, and we don't know their likelihood even with stage 1 or 2 disease. But someone that you're concerned about their risk of recurrence, they still remain at risk of recurrence. And while we do not think, based on the POSITIVE data and all the data that we've had from retrospective studies and other data sets collected for other reasons, that a pregnancy would worsen their outcome, we certainly don't believe that a pregnancy at this point in time will dramatically improve their outcome or as a treatment for breast cancer. That's when I have a heart to heart conversation with the patient, really acknowledging they still remain at high risk. And most of my colleagues tend to want the patient to get more endocrine therapy into their system before they take a break. We've kind of discussed this, and we want someone to get more like at least three to five years. That may be a little bit paternalistic, because, as we know, taking the break for people with a little lower risk didn't seem to worsen outcomes. Maybe it's fine. I don't know that a break at five years is any better than a break at two years. I don't know. Hatem, how do you handle this in your practice?   Dr. Hatem Azim: Well, I completely agree with you, Ann. I mean, it's very much decided on a patient by patient basis. The level of uncertainty that some patients accept to take is not necessarily like others. And sometimes we as physicians, we adopt this. I agree with this paternalistic approach. Nevertheless, it's very important for the patient who is 32, is not necessarily counseled like the patient who's 39, and her acceptance and the feasibility of waiting a bit longer as well in order to attempt pregnancy - the success of pregnancy afterwards is not necessarily the same. So I'm not sure we could adapt a one size fits all approach here. And I do not necessarily tend to factor much the elements around the stage. I think my point to patients is usually, well, you do have give and take this amount of risk of relapse, for example, and whether we accept to take such, what we could refer to as relatively unconventional approach of temporary interrupting endocrine therapy, and when we are comfortable to go ahead with this journey, depending on the feasibility of getting pregnant afterwards as well. So, yeah, I completely agree. It's very customized, based on and tailored according to the patients' situation. Giselle Carvalho: Thank you. I really appreciate your response to this. So, moving forward, tamoxifen alone was the most commonly prescribed endocrine therapy, followed by tamoxifen plus ovarian function suppression. The latter was preferred over aromatase inhibitors ovarian function suppression in the selected population. Endocrine therapy prescription changed in the second half of the recruitment period after July 2017 across all continents, likely due to the results of the SOFT and TEXT trials. It demonstrated absolute improvements in all disease outcomes by escalating endocrine therapy, which was more clinically meaningful in patients with high risk disease. Dr. Azim, how do you imagine this change could impact positive outcomes? Dr. Hatem Azim: Honestly, I'm not necessarily sure that it impacts significantly the way you interpret the data and the way we counsel our patients. So, in our study, some 50% of patients received GnRH analogs and around 15% received AI. And most of the patients, I would say, were recruited in the second half of the study after we had the results from, for example, SOFT and TEXT. Furthermore, as we alluded to earlier, we had 60% of patients who received chemo. So most of our patients had a stage 1 and 2 disease in which you would argue that the absolute difference between the different hormonal therapy options is not necessarily massive. Whether or not this would impact much, I'm not sure. I think the main counseling recommendations would apply, that patients who receive endocrine therapy would be asked to interrupt it for at least three months and then they attempt pregnancy afterwards. I don't know what you think, Anne, but I'm not sure that if we have more patients, and this is pretty much the case now, we have more patients treated with AI. I tend to do this a lot, especially if I'm thinking of interrupting, so I think I'm giving them maybe the best option first. I'm not sure this is necessarily, I mean, affecting me much, while interpreting that it does not appear that temporary interruption on the short term has an impact. Dr. Ann Partridge: I completely agree with your strategy. Depending on the patient and their tolerance, if they have enough risk to warrant ovarian suppression with AI or tamoxifen, of course I recommend that. And yet, at the same time, I agree with you in this group that was in POSITIVE, I think the groups are relatively low enough risk. Although 40% had no positive disease, the majority got chemo, so they weren't that low risk. And so I think over time, these kinds of patients are more and more going to get ovarian suppression. I'm doing that more in my practice as tolerated. And I hope that all that means is that their breast cancer outcomes will be better independent of a pregnancy. Giselle Carvalho: And on the topic of women with higher risk disease, CDK4/6 inhibitors are now used in the high risk adjuvant setting. How do you envision this impacting fertility? Dr. Hatem Azim: Well, this is a very good question. Of course, this is something, this is an area of research that we have to address. Some analysis from some of the adjuvant studies, for example, the PENELOPE-B, I think they reported on some of the results of their study in which they were evaluating palbociclib in the adjuvant setting and did not appear that there was significant differences in terms of the level of estradiol levels and FSH and anti-Müllerian hormone, for example. I think these were the parameters that were evaluated in this study. So, of course, more information. Of course, palb is not the CDK4/6 inhibitor approved in the adjuvant setting. So we need more information as well about the other CDK4/6 inhibitors and longer follow-up.  In my view from a counseling perspective, I think maybe you would have a certain level of uncertainty regarding whether or not this could have a mental impact on fertility. But the concept as well of possibly proposing a temporary interruption as we adopted in POSITIVE, would still apply. These patients would be treated as well, often, because if they are receiving CDK4/6 inhibitors in the adjuvant setting, it means that they have a high stage disease, so often they will be treated as well with GnRH analogs. I would counsel them pretty much the same, acknowledging a certain level of uncertainty regarding the data we have today on CDK4/6 inhibitors. Dr. Ann Partridge: Yeah, if they got a full course, they would generally be further out than many people on POSITIVE, because we treat with, for example, the abemaciclib for two years and then you want to wash out and things like that. In POSITIVE, the average was two years. And so you'd expect people of higher risk to be a little further out, which I think would make everybody a little more comfortable too, because someone who's very high risk, you'd worry about very early bad recurrence, too. Giselle Carvalho: Yeah. Thank you. So, Dr. Partridge, regarding adherence to endocrine therapy resumption after the two year break, what was the percentage of patients who resumed treatment and which strategies would you suggest to increase adherence in this case? Dr. Ann Partridge: That's a really great question. In the study, it was well over 70%, which is actually higher than you see in the general population of breast cancer survivors, especially young women. So in some cases, and I can tell you anecdotally, I experienced in my clinic that patients were more likely to start and take their endocrine therapy when they had the promise of the POSITIVE trial, to take a break to have a baby, because some of them don't want to start it, let alone stay on it, if they're told they have to take a full five to ten years. So it actually promoted adherence, ironically. And then for the people who got back on in the real world, the data suggests that by four years, somewhere close to half to 30% to half are no longer taking it. And so in POSITIVE it was, I think, 74% got back on, and that was only at the time point cut off when we did the initial primary data report. And of course more people will have gone back on because some people were still having babies and in the middle of things. And so I think that it's not as much of an issue with POSITIVE. In part, these are very compliant people, right? They're participating in a clinical trial to share the data with the rest of the world. They could have gotten pregnant on their own and they want to do it with their doctors. And so I think this is a little bit of a different group, but it was very reassuring to see that most people got on hormonal therapy after their interruption. Giselle Carvalho: And recurrence of hormone receptor positive breast cancer may occur late. How long do you plan to follow patients enrolled in the POSITIVE trial? Dr. Ann Partridge: So our plan is to follow them for at least 10 years. And it's interesting because we're starting to get close to that. We started enrollment in 2015, so I saw someone earlier this week who will have her 10 year mark next year because she got on in 2015. And that's very exciting. Obviously, it would be great to follow them even longer because ER positive breast cancer can recur many years later. But I do think that we feel as though at least 10 years will give us a good, very evidence-based feeling about the safety. Giselle Carvalho: Thank you. Thanks for sharing. With enrollment occurring at 116 institutions in 20 countries across four continents, this representation of different races and ethnicities provides strength to support this recommendation for this group of patients worldwide. Dr. Azim, what are your hopes for future analysis from this study and what future research in the area are you planning or would like to see performed?  Dr. Hatem Azim: So Ann mentioned, of course, it would be crucial to conduct the long term follow up of these patients, and provide more reassuring evidence on the safety of this approach of adjuvant endocrine therapy. So this is something we're really looking forward to. Other analysis that we are working on is the breastfeeding analysis. So looking at patients who underwent breastfeeding and how far the feasibility of this approach, obviously, but how far as well this had an impact on their breast cancer outcome. So this is something that hopefully we are going to report on soon, expected end of this year. As well, we are working on evaluating, we had a large translation research program within POSITIVE, addressing several questions, including the evolution of ovarian function parameters over time and the ovarian reserve. Also, we are working on reporting on this information. We hope that this could happen maybe in the coming year. Giselle Carvalho: Great. And finally, what advice do you give young women in your clinic who have been diagnosed with early stage hormone positive breast cancer and who are hoping to attempt pregnancy. Dr. Hatem Azim: We address these kinds of questions relatively early in their treatments and often they are very much concerned about their chance of future fertility. Usually early on, for example, before going for chemo and so on, I just share the information that this is something that we certainly could discuss and certainly there are the possibility that we could consider in the future that it's not a ‘no go' at least. And definitely it's something that we could work on once treatment is completed and recover from the adverse events of therapy. And because throughout the journey of treatments as well, women's wishes evolve over time and their perception of their pregnancy project as well evolve and change over time. So I think it's important to acknowledge, in my view, it's very important to acknowledge that this is feasible, this is possible, and because this as well provides an important psychological boost for them. And then as the patient comes over for their follow up after therapy and so on, start understanding, getting a little bit deeper into these kind of questions regarding feasibility, timing. If they are ER positive, then if it's okay to interrupt, not to interrupt, to explain a bit better and to consider a bit better regarding what kind of risk we're talking about. Articulating better, what do we mean by risk? So that sometimes you have a patient that is willing to accept a 10% risk, although others 1% risk for them represent a major threat. Also, it matters nulliparous versus a patient who already has two or three kids. So I think I tend to go a bit more granular in this kind of information as patients are out of chemo and on hormonal therapy and start addressing these matters. But I think it's important early on to share the information that nowadays we do have sufficient information not to discourage women who would like to have a pregnancy in the future. Giselle Carvalho: Thank you. Thank you. Dr. Partridge, would you like to add some final comments on this? Dr. Ann Partridge: Yeah, I think this is just such an important issue for our young breast cancer survivors and cancer survivors diagnosed at a young age, regardless of the type of cancer. So I think paying attention to this at diagnosis and through their survivorship is critical, both for their thriving in survivorship as well as for their long term health and cancer outcomes. Getting back to that adherence issue, people, if they're unhappy, won't do all the right things for themselves, sometimes medically and emotionally. And we know that infertility can be associated with long term distress for patients with and without cancer. So we need to pay attention to this and I'm really happy that ASCO is doing a podcast on this and I'm really happy that JCO is doing a podcast on this.  Giselle Carvalho: Thank you. I really would like to thank you both, Dr. Azim and Dr. Partridge for attending this interview. This is Giselle Carvalho. Thank you for listening to JCO Article Insights. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  Dr. Azim Employment Company name: Pierre Fabre, EMERGENCE THERAPEUTICS Stock and Other Ownership Interests Company name: Innate Pharma, Diaacurate Travel, Accommodations, Expenses Company name: Novartis Dr. Partridge Research Funding Company name: Novartis Patents, Royalties, Other Intellectual Property Company name: UpToDate    

In this episode, this week the boys are discussing about the Ambani Wedding and Donald Trump & more factsTISS is a weekly podcast where Varun, Kautuk, Aadar & Azim discuss Crazy weather Stories & Crazy "facts" they find on the internet. So come learn with them...or something like that. To support TISS, check out our Instamojo: www.instamojo.com/@TISSOPFollow #TISS Shorts where we put out videos: https://bit.ly/3tUdLTCYou can also check out the podcast on Apple podcast, Spotify and Google podcast!http://apple.co/3neTO62http://spoti.fi/3blYG79http://bit.ly/3oh0BxkCheck out the TISS Sub-Reddit: https://bit.ly/2IEi0QsCheck out the TISS Discord: / discord Buy Varun Thakur's 420 Merch - http://bit.ly/2oDkhRVSubscribe To Our YT ChannelsVarun - https://bit.ly/2HgGwqcAadar - https://bit.ly/37m49J2Neville - https://bit.ly/2HfYlWyKautuk - https://bit.ly/3jcpKGaFollow Us on Instagram.Varun - / varunthakur Aadar - / theaadarguy Neville - / nevilleshah. Kautak - / cowtuk Azim- https://www.instagram.com/azeembanatwalla/?hl=en Producer- Rupika KhereChannel Artwork by Sidhi SurteThumbnail - Jay Sureka

Azim ve çalışkanlıkla beraber gerçekten şansın senin yanında olduğuna inandığında mucizeleri kendine nasıl çekebileceğini gösteren bir sohbet. Dilara Aydın'la küçük yaşta başlayan kariyerinde nasıl ilerlediğini, hayatın onu nasıl sorumluluk sahibi ve azimli bir insan yaptığını, şimdi içerik üreticiliğinin yanında sürdürdüğü girişimlerini konuştuk. Dilara'yı Instagram'da @dilaraaydin hesabından takip edebilirsin. Bölümün sponsoru Hiwell'den ilk terapi seasında 10% indirim kullanmak için⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠buraya tıkla⁠⁠⁠⁠⁠⁠ ve yoldayiz10 indirim kodunu kullan!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Desté kartlarını incelemek, satış kanallarını görmek için ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠web sitesine uğra thisisdeste.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Intagram'dan takip etmek için tıkla ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@thisisdeste⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Desté'nin uygulamasını indirmek için ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠tıkla.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Flov Studio Online'da düzenli olarak yenileri eklenen yüzlerce yoga ve meditasyon dersini sınırsız izlemek ve ay ritüellerine katılmak için ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠flovstudio.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 

This is the Catch Up on 3 Things for the Indian Express and I'm Flora Swain.It's the 22nd of May and here are today's headlines.Almost a month after issuing notices to Bharatiya Janata Party president J P Nadda and Congress chief Mallikarjun Kharge over alleged Model Code of Conduct violations by their star campaigners, the Election Commission of India today directed BJP star campaigners not to make communal speeches and those of the Opposition party to refrain from saying the Constitution may be abolished. While the EC did not name PM Modi or Rahul Gandhi, it asked Nadda and Kharge for their “comments” on the “star campaigners” alleged MCC violations.The Supreme Court today declined to entertain former Jharkhand chief minister Hemant Soren's plea seeking interim bail on money laundering charges in a land scam-related case to campaign for the Lok Sabha elections. The court said his bail plea was pending before the trial court when he approached the apex court seeking the relief. The bench was upset that Soren had not disclosed to it that the trial court had taken cognisance of the complaint filed by the Enforcement Directorate (ED).Three days after two young software engineers were killed after their motorcycle was hit by a speeding Porsche car, allegedly being driven by a 17-and-a-half-year-old boy, the Juvenile Justice Board (JJB) today issued a notice to him to appear before it. According to sources, the JJB, which had earlier granted him bail, issued the notice to the boy, the son of a city-based realtor, through his lawyers and that he would appear before the Board.Questioning Delhi Chief Minister Arvind Kejriwal's silence in the case filed by Aam Aadmi Party Rajya Sabha MP Swati Maliwal against Kejriwal's aide Bibhav Kumar, Goa Chief Minister Pramod Sawant today claimed Kejriwal is putting pressure on Maliwal for a “compromise” in the matter. Sawant said, quote, “While campaigning, people have asked me only one question. Why is Kejriwal silent on the Maliwal case for the past nine days? He should give some clarification. His silence on this issue reveals everything. AAP has become an anti-Delhi and an anti-women party now.” Unquote.Bangladesh MP Anwar Ul Azim, who has been missing for the past eight days from Kolkata is feared to have been murdered, police said today. Though police sources said that blood stains were found at Azim's flat, they are still searching for the MP's body. They have collected CCTV footage from the flat. The police said the legislator of Bangladesh's ruling Awami League came to Kolkata on May 12 through the Gende border in West Bengal's Nadia district and first went to the house of one of his friends.This was the Catch-Up on the 3 Things by The Indian Express.

Religious courts or councils have long existed in England and Wales, offering mediation or arbitration on a range of issues for the Jewish, Muslim and even Christian communities. With the recent establishment of the Sikh Council, Azim Ahmed discusses the nature of these institutions with a panel of guests. What are they, what do they do, and how effective are they?Azim is joined by Dr Samia Bano, Reader in Law at SOAS, University of London; Rabbi Jonathan Romain, Convenor of the Reform Beit Din, and Professor Russell Sandberg.

Is diversity simply a box-checking exercise, or does it hold a deeper significance in academia? Today we're joined by Azim Shariff, Ph.D, a distinguished professor of psychology at the University of British Columbia, to explore the complex landscape of Diversity, Equity, and Inclusion (DEI) in higher education. In this conversation, John Tomasi and Azim delve deep into the multifaceted approach to DEI, discussing the pressing need to rethink and clarify the rationale behind diversity in faculty hiring and beyond.Azim provides a fresh perspective on managing and harnessing diversity's paradox of fostering innovation and coordination challenges. Whether it's the impact of role models on educational outcomes or the intricate balance between meritocracy and social justice motives, this episode promises to unfold the nuanced dynamics of DEI efforts within academic institutions.Get ready to challenge your understanding of diversity in academia as we navigate through the meritocratic, social justice, and instrumental values driving DEI initiatives. In This Episode:Rethinking DEI in academiaBalancing truth-seeking and social justiceThe challenges of interdisciplinary research diversityHow role models impact education outcomesClarifying the motives behind faculty diversity Follow Azim on X here: https://twitter.com/azimshariff About Azim:Azim Shariff is a Professor and Canada 150 Research Chair at the University of British Columbia, where he directs the Centre for Applied Moral Psychology. His research on morality, religion, politics, and technology regularly receives global media coverage and has appeared in top academic journals such as Science, Nature, and the Proceedings of the National Academy of Sciences. He has written about this work for The New York Times and Scientific American and has spoken at TED, the Aspen Ideas Festival, and the World Science Festival in New York. He is a fellow of the Association for Psychological Science and a Kavli Fellow of the National Academy of Sciences. He teaches a free Massive Online Open Course (MOOC) on The Science of Religion for the public through edX. Professor Shariff earned his doctorate from UBC in 2010 and returned as a faculty member in 2018. Follow Heterodox Academy on:Twitter: https://bit.ly/3Fax5DyFacebook: https://bit.ly/3PMYxfwLinkedIn: https://bit.ly/48IYeuJInstagram: https://bit.ly/46HKfUgSubstack: https://bit.ly/48IhjNF

Tasfia Azim is my latest guest. I caught up with the PH.D student last week just after an early morning run in Houston. We get into how training has been for this Boston, dealing with imposter syndrome, and why the race in Boston may not be the most exciting part of her day. Enjoy getting to know Tasfia.

This is our unabridged interview with Azim Khamisa. How do you forgive the man who killed your son? In 1995, Azim Khamisa's only son Tariq was shot and killed while delivering a pizza. The killer was a 14-year-old gang member named Tony Hicks, and due to a recent change of law in the state of California, Tony was tried as an adult and sentenced to 25 years to life in prison. But instead of responding with a call for outrage or revenge, Azim did the unthinkable: he forgave his son's killer, and he fought for his release. “My interpretation of this tragedy was that there are victims at both ends of the gun,” he says. In this episode, he tells the full story of how he uses his experience to help end youth violence, even recruiting his son's killer to join in the work. It is one of unimaginable grief, staunch faith, and unwavering compassion. Show Notes: Similar episodes Forgiving My Mother's Murderer: Sharon Risher Burying 250 Friends: Greg Boyle on Community Amidst Gang Violence Resources mentioned this episode TKF's website Azim's website Azim's TED Talk Email Azim: azim@azimkhamisa.com PDF of Lee's Interview Notes Link to Transcript for Abridged Episode JOIN NSE+ Today! Our subscriber only community with bonus episodes, ad-free listening, and discounts on live shows Subscribe to episodes: Apple | Spotify | Amazon | Google | YouTube Follow Us: Instagram | Twitter | Facebook | YouTube Follow Lee: Instagram | Twitter Join our Email List: nosmallendeavor.com See Privacy Policy: Privacy Policy Amazon Affiliate Disclosure: Tokens Media, LLC is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.

How do you forgive the man who killed your son? In 1995, Azim Khamisa's only son Tariq was shot and killed while delivering a pizza. The killer was a 14-year-old gang member named Tony Hicks, and due to a recent change of law in the state of California, Tony was tried as an adult and sentenced to 25 years to life in prison. But instead of responding with a call for outrage or revenge, Azim did the unthinkable: he forgave his son's killer, and he fought for his release. “My interpretation of this tragedy was that there are victims at both ends of the gun,” he says. In this episode, he tells the full story of how he uses his experience to help end youth violence, even recruiting his son's killer to join in the work. It is one of unimaginable grief, staunch faith, and unwavering compassion. Show Notes: Similar episodes Forgiving My Mother's Murderer: Sharon Risher Burying 250 Friends: Greg Boyle on Community Amidst Gang Violence Resources mentioned this episode TKF's website Azim's website Azim's TED Talk Email Azim: azim@azimkhamisa.com PDF of Lee's Interview Notes Transcription Link JOIN NSE+ Today! Our subscriber only community with bonus episodes, ad-free listening, and discounts on live shows Subscribe to episodes: Apple | Spotify | Amazon | Google | YouTube Follow Us: Instagram | Twitter | Facebook | YouTube Follow Lee: Instagram | Twitter Join our Email List: nosmallendeavor.com See Privacy Policy: Privacy Policy Amazon Affiliate Disclosure: Tokens Media, LLC is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.

Andy Scott and Gary Logan are joined by this week's special guest Ben Shalom to discuss the epic British heavyweight title fight between Fabio Wardley and Frazer Clarke that ended in a draw. Shalom then reveals how negotiations are coming along for a fight between Adam Azim and Harlem Eubank. Chris Kongo also joins to talk about his win over Florian Marku on the undercard and Isaac Chamberlain gives his take on the melee that took place after Viddal Riley's victory over Mikael Lawal.

BEN SHALOM HITS BACK AT EDDIE HEARN ON SMITH-AZIM PURSE BID / RESPONDS TO 'FRAUDULENT' TIMES ARTICLE Learn more about your ad choices. Visit podcastchoices.com/adchoices

BEN SHALOM HITS BACK AT EDDIE HEARN ON SMITH-AZIM PURSE BID / RESPONDS TO 'FRAUDULENT' TIMES ARTICLE Learn more about your ad choices. Visit podcastchoices.com/adchoices

Part 2 --- Send in a voice message: https://podcasters.spotify.com/pod/show/fashion-talk/message

Jon started noticing that Talos is finding more threat actors using Telegram nowadays for their communication and coordination, so he decided to bring Azim Khodjibaev on to ask him if he was just inventing this, or if it was a real trend. Turns out it's a real trend! Azim fills listeners in on why Telegram is becoming the app of choice for APTs to publish "news," threaten data leaks, and more. 

Fashion Lust Talk sits down with the founders and creative directors of Azim Clothing brand. We talked about what inspired their new collection and presenting it for NYFW in the Catskills. I had so much fun interviewing these guys and got some exclusive info! Listen in to find out what's next for the Azim brand. --- Send in a voice message: https://podcasters.spotify.com/pod/show/fashion-talk/message

'SIGN THE F****** CONTRACT' - Eddie Hearn RAGES at Shalom, Azim & McGuigans/TEASES Canelo RETURN/AJ Learn more about your ad choices. Visit podcastchoices.com/adchoices

'SIGN THE F****** CONTRACT' - Eddie Hearn RAGES at Shalom, Azim & McGuigans/TEASES Canelo RETURN/AJ Learn more about your ad choices. Visit podcastchoices.com/adchoices

On this week's podcast, Andy Scott and Gary Logan are joined by Hamzah Sheeraz,Adam Azim, and Viddal Riley. We speak to Hamza about his win over Liam Williams and potentially facing Chris Eubank Jr next. Adam Azim discusses his win over Enock Poulsen, Dalton Smith and why his next bout should be in Slough. Plus, Viddal Riley explains the latest with Isaac Chamberlain, the cruiserweight division, and his thoughts on Tyson Fury.

Dr. Azim Ahmed, Research Associate in British Muslim Studies at Cardiff University, discusses the late Shahab Ahmed's (no relation!) seminal work "What is Islam? The Importance of Being Islamic" leading us to identify the Anglophone as the New Persianate for the Cathay-to-California Complex. Links: Abdul-Azim Ahmed, Mind the Gap — The Textual, The Social, and Anglophone Islam https://medium.com/@AbdulAzim/mind-the-gap-the-textual-the-social-and-anglophone-islamin-shahab-ahmeds-2015-book-what-is-1e42b79e10ac Umar Faruq Abd-Allah, Islam and the Cultural Imperative https://www.theoasisinitiative.org/islam-the-cultural-imperative Originally published Sep 1, 2022 on https://youtu.be/MBUTbuBGtFw

Joshua Buatsi and Dan Azeez join Andy Scott and Gary Logan at Wembley Arena ahead of their highly anticipated clash, hear from both fighters ahead of this weekend's fight. Gary runs down the undercard that features Caroline Dubois, Adam Azim, and Ben Whittaker. We also look at the headlines from the boxing world including the latest from Tyson Fury vs Oleksandr Usyk, Callum Smith, and more!

In light of the discovery of a rare medieval cemetery in the Vale of Glamorgan, Azim Ahmed explores funerary customs today. Dr Andy Seaman, a specialist in early medieval archaeology from the University of Cardiff, shares his findings on location at the archaeological dig site near Fonmore Castle. While graveyards might be seen as quiet reflective places today, Andy explains that in the medieval period they were often central to life and where communities might meet to undertake business, meetings and even feasting. Dr Marianne Rozario from the Christian think tank Theos shares the conclusions from their recent report ‘Ashes to Ashes: Beliefs, Trends and Practices in dying, death and the Afterlife.' Key findings are a growing trend towards cremation rather than burial in the UK and a rise of “celebrations of life” over traditional funerals. Author, eulogy speechwriter, and funeral celebrant Pete Billingham explains how the growth of ‘Direct Cremations' is changing the way we remember those we've loved and lost, and how the digital age is shaping the modern landscape of memorial services. Near Llandaff Weir Vimla Patel shows Azim a new multi-faith ash scattering site in the River Taff. It's the first site of its kind in Wales and offers Hindus and Sikhs the opportunity to scatter the ashes of their loved ones near the place they call home. Traditionally ashes would be scattered in India's holiest river, the Ganges, but Vimla explains that for second and third generation members of the Sikh and Hindu communities many would prefer ashes to be scattered in Wales. Supporting Humanity is an award-winning charity providing mental health and bereavement support. Since the Covid pandemic they've been running workshops and tutorials to train younger members of the Muslim community the traditional Muslim funeral ritual of Ghusl. In the Islamic tradition it is important that burial takes place as quickly as possible and that the body should be washed and dressed before so. Trustee Sumaiya Khoda and CEO and founder Idris Patel share how they've been overwhelmed with the interest and dedication shown by the young people they work with. Details of organisations offering information, advice and support with bereavement are available at www.bbc.co.uk/actionline.

Today we've got the one and only Anjuli "Kiki" Azim in studio! We met Kiki on a recent project and her story and passion for life are nothing short of amazing.Not only has she traveled the world on motorcycles but she also founded the humanitarian moto tour Rebels with a Cause, which is truly inspirational.Kiki is a rider, photographer, storyteller, and energetic soul who lives life to the fullest despite fighting battles that would crush most.KIKI'S INFO:-Website - https://www.rebelstour.com/#About-Instagram - https://www.instagram.com/ainjul/-Donate: Rebels with a Cause Humanitarian Ride - https://givebutter.com/E4C-Rebels-With-A-Cause-Help Kiki Kick Chronic Lyme Disease - https://www.gofundme.com/f/help-kiki-kick-chronic-lyme-diseaseAbout Rebels with a Cause:"Embark on a transformative trip filled with purpose and thrilling adventure. We commence in the lush green bustling capital of Pakistan, Islamabad, then fly over lofty mountains, rocks, fawn sand and snow to Skardu- The gateway to the best treks and mountaineering in the world. Where we will ride segments of the Karakorams backbone containing the densest mass of glaciers, ride to serene lakes, past waterfalls and ancient as well as organic villages. Sprinkling our aid to multiple valleys along the way. This region of Gilgit-Baltistan is the rooftop of the world, with verdant forests, rolling hills, and glistening rivers. It is a place of unspoiled beauty with the friendliest people you'll ever meet."OUR WEBSITE: https://2lanelife.com/  USE CODE: "YOUTUBE" FOR 10% OFF OF PARTS & ACCESSORIES2LANELIFE INSTAGRAM: https://www.instagram.com/2lanelife/GAYLIN'S INSTAGRAM - https://www.instagram.com/xerox57/LANCE'S INSTAGRAM - https://www.instagram.com/biglancec/JOSH'S INSTAGRAM - https://www.instagram.com/imridingplaces/Want to SAVE on EagleRider Rentals? - CLICK HEREABOUT 2LANELIFEWe travel the country on our Harley-Davidson motorcycles, exploring some of the best roads the country has to offer. Our goal is to share all of the neat history and attractions across the back roads, a.k.a. the 2Lanes of America using a cinematic approach unique to our experiences. Along this journey, we meet tons of amazing people, and learn something new every time. We are here to inspire travel!Friends:Thrashin' SupplyLegend SuspensionsCustom Dynamics Motorcycle LightingEagleRider Motorcycle Rentals & Tours Feuling PartsKlock WerksCobra USAMaxima Racing OilsBell HelmetsSaddlemenRockford FosgateLaw Tigers Motorcycle LawyersGET YOUR MOTORCYCLE PARTS & ACCESSORIES AT https://2lanelife.com/

This week: Innovation Forum's Ian Welsh speaks with Renaka Ramachandran, chief finance officer at Sime Darby Plantation, about some of the challenges around interim and 2050 net zero target setting, and the importance of transparency on environmental and social impacts.    They also discuss the challenges of setting baselines, and waiting for the right technology to address hard-to-abate emissions.    And, in the first of a new factory voice series, Innovation Forum's Savanna Razzaque talks with Salman Azim from denim manufacturer Azim and Sons in Bangladesh. They discuss some of the initiatives the company has developed to support the wellbeing of its workforce, and the impact of climate change on production processes.   Plus, new South Pole report suggests rise in greenhushing; Drax gets the go-ahead on CCS technology development; and, Know the Chain benchmarks action on labour rights in apparel and footwear, in the news digest.    Host: Ian Welsh 

Columbia Records own Azim Rashid Talks The Music Business, 360 Deals, Music Marketing & More --- Support this podcast: https://podcasters.spotify.com/pod/show/nolazine-network/support

Trainer/manager Tunde Ajayi and European super-lightweight champion Adam Azim join Andy Scott and Barry Jones for this week's episode. Tunde tells us about his journey with Anthony Yarde and reveals what could be on the cards for the future, as Yarde eyes up the winner of Joshua Buatsi vs Dan Azeez. Adam reflects on his European title-winning night in Wolves and reveals who's next for 'The Assassin'. He also reveals how preparations of stable-mate Chris Billam-Smith are going, ahead of his first WBO cruiserweight title defence against Mateusz Masternak in his hometown, Bournemouth.

Andy Scott and Barry Jones are joined by this week's special guest Joshua Buatsi to discuss his rescheduled clash with Dan Azeez in February and what's more important to him: winning a world title or fighting domestic rival Anthony Yarde. They also discuss European title wins for Tyler Denny and Adam Azim last weekend before celebrating the news that Tyson Fury will take on Oleksandr Usyk for undisputed heavyweight supremacy next year.

Andy Clarke gets immediate reaction from the Halls in Wolverhampton to Adam Azim's European super-lightweight title win against Franck Petitjean as well as reaction to Tyler Denny's dream European championship win against Matteo Signani.

Get a hold of the luxury of flying private jets, its premium experience, and the innovation it boasts with Volato's Chief Pilot and Director of Training Azim Sumar. Listen in as he details their fleet, pilot hiring and training, and company culture. Stay tuned!   WHAT YOU'LL LEARN FROM THIS EPISODE  What Volato is all about Volato's criteria for hiring pilots A sneak peek at Volato's training profile Expected salary of a Volato pilot Policy to keep Volato pilots presentable    ABOUT AZIM SUMAR   Azim Sumar is currently the Chief Pilot and Director of Training for Volato, two responsibilities he says go hand in hand, with management being a vital component.    Volato is the modern way to purchase and operate a private jet. We have created the most innovative model in private aviation, which has resulted in us becoming one of the category's fastest-growing firms. We provide the most profitable model. You share in the revenue every time your aircraft flies a paid mission, so your investment in your aircraft is limited to that, bringing the managed aircraft concept to fractional owners.   CONNECT WITH AZIM Website: Volato LinkedIn: Volato Hiring Platforms: JSfirm | Climbto350 CONNECT WITH US    Are you ready to take your relationship to the next level? Don't wait until it's too late. Use the promo code “PODCAST” and save 10% on all our services. Check us out at www.spitfireelite.com!   If you want to recommend someone to guest on the show, email Nik at podcast@spitfireelite.com, and if you need a professional pilot resume, go to www.spitfireelite.com/podcast/ for FREE templates!    SPONSOR If you're a professional pilot looking for a great financial planning partner for your retirement, tax, and investment, go to www.tpope.ceterainvestors.com/contact or call 704-717-8900 ext 120 to schedule a consultation appointment with Timothy P. Pope, CFP®